1-4 of 4
Vladimir Semiglazov
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer

Matteo Dugo, Chiun-Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Robert S. Seitz, Tyler J. Nielsen, Marc Thill, Antonio Antón-Torres, Stefania Russo, Eva Maria Ciruelos, Brock L. Schweitzer, Douglas T. Ross, Barbara Galbardi, Richard Greil, Vladimir Semiglazov, Balázs Gyorffy, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, Olivia Blasi, Maurizio Callari, Lajos Pusztai, Pinuccia Valagussa, Giuseppe Viale, Luca Gianni, Giampaolo Bianchini
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21): 4900–4909.
https://doi.org/10.1158/1078-0432.CCR-24-0149
Published: 01 November 2024
View articletitled, The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Open the PDF for The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Aleix Prat, Giampaolo Bianchini, Marlene Thomas, Anton Belousov, Maggie C.U. Cheang, Astrid Koehler, Patricia Gómez, Vladimir Semiglazov, Wolfgang Eiermann, Sergei Tjulandin, Mikhail Byakhow, Begoña Bermejo, Milvia Zambetti, Federico Vazquez, Luca Gianni, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (2): 511–521.
https://doi.org/10.1158/1078-0432.CCR-13-0239
Published: 16 January 2014
View articletitled, Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
Open the PDF for Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study in another window
Includes: Supplementary data
Journal Articles

Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor–Positive Locally Advanced or Metastatic Breast Cancer

Nuhad K. Ibrahim, Kemal O. Yariz, Ihor Bondarenko, Alexei Manikhas, Vladimir Semiglazov, Anna Alyasova, Volodymyr Komisarenko, Yaroslav Shparyk, James Lee Murray, David Jones, Shai Senderovich, Albert Chau, Fredrik Erlandsson, Gary Acton, Mark Pegram
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (21): 6822–6830.
https://doi.org/10.1158/1078-0432.CCR-11-1151
Published: 31 October 2011
View articletitled, Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor–Positive Locally Advanced or Metastatic Breast Cancer
Open the PDF for Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor–Positive Locally Advanced or Metastatic Breast Cancer in another window
Journal Articles

Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy

Luca Gianni, José Baselga, Wolfgang Eiermann, Vicente Guillem Porta, Vladimir Semiglazov, Aña Lluch, Milvia Zambetti, Dolores Sabadell, Günther Raab, Antonio Llombart Cussac, Alla Bozhok, Angel Martinez-Agulló, Marco Greco, Mikhail Byakhov, Juan Josè Lopez Lopez, Mauro Mansutti, Pinuccia Valagussa, Gianni Bonadonna, European Cooperative Trial in Operable Breast Cancer Study Group
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (24): 8715–8721.
https://doi.org/10.1158/1078-0432.CCR-05-0539
Published: 16 December 2005
View articletitled, Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy
Open the PDF for Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy in another window